If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Humulin®
- Full Prescribing Information
Humulin® R (U-100) (regular insulin human injection, USP [rDNA origin])
100 units/mL - Full Prescribing Information
Humulin® R (U-500) (regular U-500 [concentrated] insulin human injection, USP [rDNA origin])
500 units/mL - Full Prescribing Information
Humulin® 70/30 (70% human insulin isophane suspension and 30% human insulin injection [rDNA origin])
100 units/mL - Full Prescribing Information
Humulin® N U-100 (human insulin [rDNA origin] isophane suspension)
100 units/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Humulin Insulins®: Transitioning to Novolin Insulins®
Eli Lilly and Company has conducted no clinical studies evaluating the safety and efficacy of transitioning from Novolin® to Humulin®, or vice versa.
Lilly has conducted no clinical studies evaluating the safety and efficacy of transitioning patients with either T1DM or T2DM from Novolin to Humulin or vice versa.
Changes that may affect glycemic control and predispose patients to hypoglycemia or hyperglycemia include changes in
insulin
manufacturer
type, or
method of administration. 1-4
Any change of insulin should be made cautiously and only under medical supervision. The frequency of BG monitoring should be increased. 1-5
Some patients taking Humulin may require a change in dosage from that used with other insulins. If an adjustment is needed, it may occur with the first dose or during the first several weeks or months.3
Enclosed Prescribing Information
HUMULIN® R U-100 (insulin human injection), for subcutaneous or intravenous use, Lilly
HUMULIN® R U-500 (insulin human injection), for subcutaneous use, Lilly
1. Humulin 70/30 [patient package insert]. Indianapolis, IN: Eli Lilly and Company; 2017.
2. Humulin N [patient package insert]. Indianapolis, IN: Eli Lilly and Company; 2017.
3. Humulin R U-100 [package insert]. Indianapolis, IN: Eli Lilly and Company; 2018.
4. Humulin R U-500 [patient package insert]. Indianapolis, IN: Eli Lilly and Company; 2016.
5. Novolin R [package insert]. Princeton, NJ: Novo Nordisk Pharmaceuticals, Inc.; 2013.
Glossary
Lilly = Eli Lilly and Company
T1DM = type 1 diabetes mellitus
T2DM = type 2 diabetes mellitus
Date of Last Review: July 30, 2018
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 8am - 7pm ET
